European Case Law Identifier: | ECLI:EP:BA:2012:T010709.20120712 | ||||||||
---|---|---|---|---|---|---|---|---|---|
Date of decision: | 12 July 2012 | ||||||||
Case number: | T 0107/09 | ||||||||
Application number: | 93102279.2 | ||||||||
IPC class: | C07K 14/725 C12P 21/08 A61K 39/395 |
||||||||
Language of proceedings: | EN | ||||||||
Distribution: | B | ||||||||
Download and more information: |
|
||||||||
Title of application: | The CD40CR receptor and ligands therefor | ||||||||
Applicant name: | Bristol-Myers Squibb Company Trustees of Dartmouth College doing bussiness as Dartmouth College The General Hospital Corporation doing business as Massachusetts General Hospital |
||||||||
Opponent name: | Biogen Idec MA Inc. | ||||||||
Board: | 3.3.04 | ||||||||
Headnote: | - | ||||||||
Relevant legal provisions: | |||||||||
Keywords: | Extension beyond the content of the application as filed (yes) Right to priority (no) - deposit of biological material after the filing date of the earlier application Inventive step (no) Decisions and legal literature cited: G 0002/93, G 0002/98, G 0001/03, T 0542/95, T 0939/92, T 0133/01, T 0512/02, T 0931/04, T 1589/05; "In re Lundak", 773F.2d 1216, Fed.Cir. 1985 BGH X ZR 89/07 "Olanzapin" Europäisches Patentübereinkommen: Münchner Gemeinschaftskommentar, eds.: Beier, Haertel, Schricker; 15th edition, April 1991, Art. 53, Moufang, R. Patentgesetz mit EPÃ, ed.: Schulte, R.; 8th edition, 2008 "Notice of the European Patent Office dated 18 July 1986 concerning European patent applications and European patents in which reference is made to microorganisms", EPO OJ 1986, 269-275 "Notice from the European Patent Office dated 7 July 2010 concerning inventions which involve the use of or concern biological material", EPO OJ 2010, 498-513 |
||||||||
Catchwords: |
See points 6 to 26 of the Reasons |
||||||||
Cited decisions: |
|
||||||||
Citing decisions: |
|
Source: http://www.epo.org/law-practice/case-law-appeals/recent/t090107eu1.html
Date retrieved: 17 May 2021